Certainly, PRKD2 has an important regulatory role in TFH development and further work examining the effects of increasing the kinase activity of Prkd2 in CD4 + T cells is warranted, not only for PSC, but also for T1DM for which this is a shared risk locus. This evidence concerns the gene CD4 and type 1 diabetes mellitus.